The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Psoriatic Arthritis Patients Show Long-Term, Sustained Improvement with Secukinumab

Psoriatic Arthritis Patients Show Long-Term, Sustained Improvement with Secukinumab

November 20, 2018 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Secukinumab has shown sustained improvement in active psoriatic arthritis (PsA) signs and symptoms over four years. Reported during the 2018 ACR/ARHP Annual Meeting in October, these results are from the FUTURE 2 study, a long-term, four-year safety and efficacy study with dose escalation in patients with active PsA.1 Secukinumab is a fully human, monoclonal IgG1 antibody that selectively neutralizes IL-17A.

You Might Also Like
  • Secukinumab Effective for Treating Psoriatic Arthritis
  • Secukinumab Effective for Psoriatic Arthritis
  • Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA
Explore This Issue
December 2018
Also By This Author
  • Bimekizumab Promising for PsA

In the study, patients (N=397) were randomized to receive 300 mg secukinumab, 150 mg secukinumab, 75 mg secukinumab or placebo weekly. At Week 8, patients received the treatment or placebo every four weeks. At Week 128, if a patient still had active signs of disease, based on physician judgment, the dose was escalated: from 150 mg to 300 mg secukinumab, or from 75 mg to 150 mg or 300 mg secukinumab. Week 208 assessments included ACR20, ACR50, ACR70, PASI 75, PASI 90, HAQ-DI, SF-36 PCS and dactylitis and enthesitis resolution.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Of all the randomized patients, approximately one-third had inadequate response to prior anti-tumor necrosis factor (TNF) alpha use. Analyses were conducted on prior anti-TNF users, as well as on patients who used or did not use concomitant methotrexate. For secukinumab-treated patients who were anti-TNF alpha therapy naive, 71–77% achieved ACR20. For patients who were anti-TNF alpha therapy inadequate responders, 60–71% achieved ACR20. Patients who used concomitant methotrexate had ACR20 responses of 68–79%. And patients who did not use concomitant methotrexate had ACR20 responses of 59–75%.

Patients tolerated the treatment well. The study concluded that secukinumab led to sustained improvement in the signs and symptoms of PsA over four years. Secukinumab treatment effectiveness was sustained or further improved after dose escalation.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The incidence, type and severity of adverse events were consistent with previous reports. Treatment-emergent anti-drug antibody was reported in three patients, with no neutralizing antibody or efficacy loss. Only one death, due to sepsis, was reported during the study in a patient who received 150 mg secukinumab.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

Reference

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
  1. McInnes IB, Kivitz AJ, Nash P, et al. Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: Long-term (four year) data from a phase 3 study [abstract]. Arthritis Rheumatol. 2018;70(suppl 10).

Filed Under: Conditions Tagged With: Psoriatic Arthritis, secukinumabIssue: December 2018

You Might Also Like:
  • Secukinumab Effective for Treating Psoriatic Arthritis
  • Secukinumab Effective for Psoriatic Arthritis
  • Phase 3 Trials: Secukinumab for Psoriatic Arthritis & DA-DKP for OA
  • Secukinumab Promising for Sustained Improvements in Palmoplantar & Nail Psoriasis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)